



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/83628/2020

European Medicines Agency decision P/0070/2020

of 18 March 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant) (EMA-001220-PIP05-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0070/2020

of 18 March 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant) (EMA-001220-PIP05-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Eli Lilly and Company Limited on 22 April 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 January 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for baricitinib (Olumiant), tablet, age-appropriate liquid oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for baricitinib (Olumiant), tablet, age-appropriate liquid oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for baricitinib (Olumiant), tablet, age-appropriate liquid oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Eli Lilly and Company Limited, Lilly Research Center, Erl Wood Manor, Sunninghill Road, GU20 6PH - Windlesham, Surrey, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/618655/2019
Amsterdam, 31 January 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001220-PIP05-19

Scope of the application

Active substance(s):

Baricitinib

Invented name:

Olumiant

Condition(s):

Treatment of systemic lupus erythematosus

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Age-appropriate liquid oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Eli Lilly and Company Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company Limited submitted for agreement to the European Medicines Agency on 22 April 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 28 May 2019.

Supplementary information was provided by the applicant on 28 October 2019. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of systemic lupus erythematosus.

The waiver applies to:

- the paediatric population from birth to less than 5 years of age;
- tablet, age-appropriate liquid oral formulation, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments;

2. Paediatric investigation plan

2.1. Condition:

Treatment of systemic lupus erythematosus

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric systemic lupus erythematosus

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet, age-appropriate liquid oral formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1: Development of an age-appropriate liquid oral formulation
Non-clinical studies	0	Not applicable
Clinical studies	1	Study 2: Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, efficacy and safety of baricitinib in children from 5 to less than 18 years of age with active systemic lupus erythematosus (SLE) (I4V-MC-JAJF)

Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic idiopathic arthritis

Authorised indication(s):

- Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.

Authorised pharmaceutical form(s):

Film-coated tablet (tablet)

Authorised route(s) of administration:

Oral use